28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too

Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.